At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Fluenz +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of an Endotoxin Challenge on the Immune Response Elicited by a Subsequent Challenge With Fluenz in Healthy Volunteers, an Explorative Study
In Brief
A clinical study evaluating Fluenz, placebo, and 1 other intervention for Innate Immune Response and Immune Tolerance. Completed, enrolled 30 participants.
Detailed Summary
To evaluate the bacterial-viral interactions between LPS and Fluenz as a model for sepsis (bacterial) and Influenza (viral) infections which are common and associated with high mortality rates in the ICU. To understand these interactions is important for the development of preventive and therapeutic interventions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInnate Immune Response, Immune Tolerance
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedDec 2015
Primary CompletionJan 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedDec 30, 2015
Enrollment StartDec 1, 2015
Primary CompletionJan 1, 2017
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.5 years ago
Interventions
Fluenzbiological
intranasal inoculation with Fluenz
placeboother
LPSother